SCHEMBL4711046

SCHEMBL4711046

Fc1ccc(C(c2ccc(F)cc2)c2c(F)cccc2F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.40
IDO1 P14902 2/20 0.38
TDO2 P48775 2/20 0.38
CES2 O00748 2/20 0.36
CES1 P23141 2/20 0.36
POLB P06746 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CNR1 P21554 2/20 0.33
ALDH1A1 P00352 1/20 0.33
NFE2L2 Q16236 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4083441 0.79 CES2 (0.44) GAACES2CES1ALDH1A1NFE2L2
SCHEMBL21830989 0.77 ATM (0.44) IDO1TDO2CES2CES1KMT2A
SCHEMBL22048340 0.77 DAO (0.40) GAAIDO1TDO2CES2CES1
SCHEMBL7541462 0.77 KCNH2 (0.47) GAAKMT2AALDH1A1
SCHEMBL2489611 0.76 IDO1 (0.50) GAAIDO1TDO2CES2CES1
SCHEMBL21910594 0.74 ALDH1A1 (0.36) GAAIDO1TDO2CES2CES1
SCHEMBL21367678 0.72 SLC6A2 (0.50) GAAIDO1TDO2MEN1KMT2A
SCHEMBL3690196 0.72 SLC6A2 (0.50) GAAIDO1TDO2MEN1KMT2A
SCHEMBL23409870 0.67 CYP17A1 (0.40) MEN1KMT2ACNR1ALDH1A1HDAC4
SCHEMBL18894118 0.66 CES2 (0.43) GAACES2CES1ALDH1A1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1962834-A2 USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA Aventis Pharmaceuticals Inc. (US) 2008-09-03 EP disclosed
WO-2007067617-A2 USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA AVENTIS PHARMACEUTICALS INC. (US) 2007-06-14 WO disclosed